Merck KGaA Foresees Mid-2019 US Launch Of Oral MS Therapy Mavenclad

 
• By Sten Stovall

German Merck tells Scrip Mavenclad's long spell in the regulatory 'wilderness' allowed it to amass deep safety and efficacy data that should help the oral MS drug's commercial prospects.

Nerve cells
Mavenclad Already has approval in Europe to treat highly active relapsing MS • Source: Shutterstock

More from Strategy

More from Business